. were performed by standard procedures, and the results obtained with patients' plasma were compared to those obtained with pooled normal plasma. Factor V and Factor VIII levels were measured by modifications of the methods used to determine prothrombin time (13) and partial thromboplastin time (14), respectively. Factor XIII levels were measured as described by Duckert &a.
(15). Fibrinogen concentrations were determined by the thrombin clotting time assay of Clauss (16) or by assay of the fibrin tyrosine content (17).
. . IhzadLkandbatroxoblnmedlated *_ * were studied by the following modification of the method of Gralnick & a. (18) . A fibrinogen solution (0.15 ml) in 0.3 M NaCl was equilibrated at 25'C in a cuvette with 1.35 ml of 0.06 M sodium phosphate buffer, pH 6.8. Either 10 ~1 thrombin or 50 vl batroxobin (reconstituted Reptilase-R obtained from Abbott Laboratories, North Chicago, Illinois) was added and the absorbance at 350 nm was continuously monitored in a thermostated cell compartment of a GCA/McPherson spectrophotometer.
. . m pf EEB were done with a kit from IMCO Corp., Ltd. AB Stockholm. Sweden. Samples were prepared using hirudin to inhibit the thrombin (19). m m amount pf v released upon treating fibrinogen with thrombin was measured as described previously (18) using the method of Lowry (20) to determine trichloroacetic acid (TCA)4 soluble peptides in the clot supernatant.
Fibrin monomer were prepared and subsequently aggregated by a modification of the method of Gralnick aal.
(18 and references cited therein). Fibrinogen in 0.15 M Tris-HCl buffer, 0.15 M NaCl, pH 7.4 was clotted with human thrombin. After approximately 90% of the fibrinogen had clotted. the clot was wound around a glass rod and then dissolved in 0.02 M acetic acid. Polymerization of the fibrin monomers was initiated by adding a portion of the monomer solution to a 31-fold excess of 0.06 M potasium phosphate buffer at pH 6.8 which either contained no NaCl (for runs at an ionic strength of 0.12) or 0.3 M NaCl (for runs at an ionic strength of 0.42) at 25'C.
The ~c;yoss-li&i~g af fibrin was monitored as described previously (21).
Digestion nf fibrinoeen ti
Dlasmin was carried out by a method similar to that described by Sherman fi A. (22). Plasminogen (profibrinolysin. labeled 2.5 U/mg as obtained from Sigma Chemical Co., St. Louis, Missouri) at 5 mg/ml in 0.046 M Tris-HCl, 0.115 M CaC12 pH 8.1 was activated with 100 Plough U/ml of urokinase (obtained from Calbiochem-Behring Corp.. La Jolla, California) for one hour. prior to the start of digestion.
'Abbreviations used in this paper: TCA, Trichloroacetic acid; PAGE, polyacrylamide gel electrophoresis; SDS, sodium dodecyl sulfate. . . drcrolsm m were obtained with a Jasco. J-40C automatic recording spectropolarimeter.
I;asetlistorv.
The propositus, an 80 year old Caucasian male, was first studied in 1977 prior to total hip replacement surgery. He was in excellent health, except for severe degenerative arthritis in the left hip. When studies of his clotting system indicated an abnormality, he was referred to The University of Michigan Hospital. He had no history of unusual bleeding, except in 1973 when he required two units of blood after a cholecystectomy.
Coagulation studies (Table I) demonstrated that the patient's prothrombin time and thrombin clotting times were abnormally long. The partial thromboplastin time, and Factor V and XIII levels of the propositus were normal, whereas his Factor VIII level was elevated. The fibrinogen concentration in the plasma of the propositus was abnormally low when measured using the indirect thrombin clotting time assay, and normal when measured from the tyrosine content of the fibrin. These studies suggested a diagnosis of dysfibrinogenemia, wherein the actual level of fibrinogen in the plasma was normal, but some of the fibrinogen was functionally deficient so as to give an abnormally long thrombin clotting time.
j&~j& studies. The dysfibrinogenemia was traced through four generations ( Fig. 1) . Twenty-seven of the descendants of the propositus were tested and eleven had prolonged thrombin clotting times. The apparent fibrinogen concentration based on the thrombin clotting times of affected individuals ranged from 59 mg/dl to 101 mg/dl. The Reptilase time determined for plasma from the propositus' daughter (III-4 in Fig. 1 ) was also found to be prolonged (31.5 s vs. 14.8 s for normal plasma). All affected individuals were asymptomatic; several had undergone surgery, including hysterectomy, appendectomy, cholecystectomy. and tonsillectomy with no unusual bleeding or requirements for blood products. There was no known consanguinity in the The thrombin-catalyzed cleavage of normal and abnormal fibrinogen near the amino termini of the Aa-and BB-chains, to release fibrinopeptides A and B, and the subsequent spontaneous polymerization of the fibrin monomers (24) was monitored by following the increase in turbidity of the solution caused by the polymerization reaction. Although the increase in turbidity of the solution reflects polymerization of fibrin monomers, subsequent to the thrombinmediated proteolysis of the fibrinogen, the rate at which the turbidity of a solution of fibrinogen increases upon addition of thrombin may be determined either by the rate of proteolysis or polymerization. whichever is slower. As shown in Fig. 2A . a fifteen-fold increase in the concentration of thrombin (from 2.9 U/ml to 43.7 U/ml) had no effect on the rate of thrombin-mediated polymerization of normal fibrinogen as measured from the time dependent increase in turbidity. Since the increased thrombin concentration should have increased the rate of proteolysis, this result suggests that polymerization and not proteolysis was rate limiting under the conditions used with normal fibrinogen. The fibrinogen from an affected family member displayed markedly different behavior (Fig. 2B) . At a low thrombin concentration (2.9 U/ml), thrombin-mediated polymerization of the patient's fibrinogen was much FIG. 2. Thrombin-mediated polymerization of normal fibrinogen (A), and fibrinogen from an affected individual (B). The fibrinogen (0.052 mg/ml) in 0.054 M potassium phosphate buffer, 0.027 M NaCl. pH 6.8 was treated with=. 43.7 U/ml; *, 11.3 U/ml; Andy. 2.9 U/ml thrombin.
slower than thrombin-mediated polymerization of normal fibrinogen. Moreover, increasing the concentration of thrombin, which presumably increased the rate of release of fibrinopeptide A and B, markedly increased the rate of polymerization (Fig. 2B ). These observations suggested that proteolysis of abnormal fibrinogen was rate limiting under the same conditions where polymerization of fibrin monomers was rate limiting with normal fibrinogen. Differences in the rate of thrombin-mediated polymerization of abnormal and normal fibrinogen similar to those depicted in Fig. 2 were observed at all fibrinogen concentrations studied (0.05 mg/ml to 5.7 mg/ml).
Although thrombin-mediated polymerization of the patient's fibrinogen was slower (at low thrombin concentrations) than that of normal fibrinogen, After the maximum amount of polymerization had occurred (150 min) the clots were removed from the solution, causing the optical density at 350 nm to return to zero. Thrombin (5 U) was then added to each sample.
Any increase in the absorbance of the sample is shown here as an additional rise in the absorbance at 350 nm.
. .
PolvmerrzatronpfPreformedFibrin-.
Fibrin monomers were prepared from normal fibrinogen and the patient's fibrinogen under conditions where about 90% of the fibrinogen had formed fibrin. When these monomers were dissociated at low pll, and then returned to a neutral pH. the monomers polymerized.
No signif icant differences could be detected between the polymerization (as monitored at 350 nm) of monomers from normal and the patient's fibrinogen at an ionic strength of 0.12 or 0.42. This result provided additional support for the view that the proteolysis step and not the polymerization of fibrin monomers was the altered step in the clotting of abnormal fibrinogen.
&QJ&&AL m
af JL&rin KFth Factor u. Fibrinogen preparations which had been subjected to treatment with urea to inactivate endogeneous Factor XIII (21) contaminants were clotted in the presence of CaC12, 4.4 U/ml thrombin and 1 ul/ml normal plasma so as to provide the same amount of Factor XIII to both samples. Both normal fibrinogen and the fibrinogen from an affected family member formed a-polymers and Y-dimers with the concomitant disappearance of the a-monomers and y-monomers; however, the rate of cross-linking differed in the two samples. After 15 min, the y-monomers could not be detected in the normal fibrinogen. but were still detectable in the sample of abnormal fibrinogen at one hour. After two hours, y-monomers also were no longer seen in the sample of abnormal fibrinogen.
The disappearance of a-monomers also was delayed in the sampleof abnormal fibrinogen during the first hour of incubation. The dysfibrinogenemia reported in this work is one of a class of dysfibrinogenemias which exhibit an abnormality in the release of fibrinopeptide A. Of the 14 dysfibrinogenemias (18, (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) in this class only fibrinogen Bethesda I and fibrinogen New Orleans exhibit normal polymerization of fibrin monomers as does the abnormal fibrinogen reported here. Unlike this fibrinogen, however, fibrinogen Bethesda I (18) and fibrinogen New Orleans (37) inhibit the thrombin clotting time of normal plasma, It is interesting to note that fibrinogen Metz (36). like the abnormal fibrinogen reported here, is resistant to proteolysis by batroxobin. Fibrin monomers from fibrinogen Metz, however. exhibit altered rates of polymerization. Therefore, the fibrinogen reported in this work appears to be unique. Following accepted nomenclature , we designate this new dysfibrinogenemia, fibrinogen Petoskey.
Ultimately, the dysfibrinogenemias must be distinguished on the basis of the amino acid replacement responsible for the functional alteration. As exemplified by the characterization of fibrinogen Detroit (6), knowledge of dysfibrinogenemias should greatly enhance our understanding of the complex set of interactions necessary for the conversion of circulating fibrinogen to a covalently cross-linked fibrin clot. Fibrinogen Petoskey offers a unique opportunity to determine an important structural feature of fibrinogen which is essential for its susceptibility to batroxobin and which is important for its interaction with thrombin.
